Galactosyl receptor, a cell surface C-type lectin of normal and tumoral prostate epithelial cells with binding affinity to endothelial cells

Kierszenbaum, Abraham L.; Rivkin, Eugene; Chang, Peter L.; Tres, Laura L.; Olsson, Carl A.

doi:10.1002/(sici)1097-0045(20000515)43:3<175::aid-pros3>3.0.co;2-b

Cited by 16 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other investigations suggest that ␤-1 integrins, hyaluronan, and a type C cell surface lectin expressed on the surface of PC-3 cells also may mediate PC-3-HBME interaction. 32,34,35 Previously, we demonstrated that ␤-1 integrins expressed on HBME cells did not mediate PC-3 cell adhesion to these cells. 36 It has been reported that the ␣v␤3 integrin mediates the adhesion of PC-3 and DU145 cells to cytokine-activated HUVEC monolayers.…”

Section: Pc-endothelium Interaction: Dockingmentioning

confidence: 93%

“…The effects of modified citrus pectin and galectin‐3 polyclonal antibody suggest the involvement of a lectin, whereas the RGD peptide effect suggests integrin involvement. Other investigations suggest that β‐1 integrins, hyaluronan, and a type C cell surface lectin expressed on the surface of PC‐3 cells also may mediate PC‐3‐HBME interaction 32, 34, 35…”

Section: Pc‐endothelium Interaction: Dockingmentioning

confidence: 99%

See 1 more Smart Citation

Stromal factors involved in prostate carcinoma metastasis to bone

Cooper

Chay

Gendernalik

et al. 2003

Cancer

167

124

View full text Add to dashboard Cite

show abstract

Section: Pc-endothelium Interaction: Dockingmentioning

confidence: 93%

Section: Pc‐endothelium Interaction: Dockingmentioning

confidence: 99%

Stromal factors involved in prostate carcinoma metastasis to bone

Cooper

Chay

Gendernalik

et al. 2003

Cancer

167

124

View full text Add to dashboard Cite

show abstract

“…In the present study, about 83% of the patients with prostate neoplasm had metastases both in the lymph nodes and in a distant organ at autopsy, and 75% of the patients had bone metastasis. However, it has not been fully clarified why bone metastasis is characteristic of prostate cancer, in spite of recent progressive investigations, 6,7 McNeal et al 5 revealed that extracapsular invasion was uncommon with a tumor volume of less than 0.5 ml, and metastasis was seen with a tumor volume of more than 4 ml. However, it has not been fully clarified why bone metastasis is characteristic of prostate cancer, in spite of recent progressive investigations, 6,7 McNeal et al 5 revealed that extracapsular invasion was uncommon with a tumor volume of less than 0.5 ml, and metastasis was seen with a tumor volume of more than 4 ml.…”

Section: Discussionmentioning

confidence: 99%

Autopsy findings of patients with urological neoplasms

et al. 2002

View full text Add to dashboard Cite

Background.A study was carried out to gain extensive understanding of the disease status in patients who had suffered and died of urological neoplasms. Methods. The subjects were 524 patients who had died at the Department of Urology of Gunma Cancer Center. The autopsy rate for each urological, neoplasm, the extent of the disease, and incidental diseases were analyzed. Results. Autopsies were performed in 27.1% (142/524) of the patients. Frequent metastatic sites were the lymph nodes, bone, and lung in prostate neoplasms; the lymph nodes, liver, and lung in bladder neoplasms; and the lymph nodes, lung, and bone in kidney neoplasms. In the 116 patients with these three major urological neoplasms, the autopsy findings of all patients were compatible with progression of the disease, except for 5 cases (acute myocardial infarction in 2 and liver failure in 3). Multiple primary cancers were seen in 21.6% (25/116), and other cancers that caused death, apart from those at urological sites, were confirmed in 7 patients (pancreas in 2, and esophagus, lung, gallbladder, liver, and uterus in 1 patient each). Conclusion. Autopsies revealed the macroscopic and microscopic extent of the disease and the presence of incidental disease beyond the diagnosis made in the patient's lifetime.

show abstract

“…Surprisingly, the beta-1 integrins expressed on HBME cells were not involved in PC-3 cell adhesion to HBME cell monolayers [48]; however, beta-1 integrins, expressed on PC-3 cells, did mediate its interaction with HBME cell monolayers [45]. Hyaluronan and galactosyl receptor, a cell surface C-type lectin expressed on PC-3 cells, were also shown to mediate PC-HBME interaction [49,50].…”

Section: Attachment To Endotheliummentioning

confidence: 99%

Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone

Keller¹,

Zhang²,

Cooper

et al.

Prostate Cancer: New Horizons in Research and Treatment

View full text Add to dashboard Cite

The majority of men with progressive prostate cancer develop metastases with the skeleton being the most prevalent metastatic site. Unlike many other tumors that metastasize to bone and form osteolytic lesions, prostate carcinomas form osteoblastic lesions. However, histological evaluation of these lesions reveals the presence of underlying osteoclastic activity. These lesions are painful, resulting in diminished quality of life of the patient. There is emerging evidence that prostate carcinomas establish and thrive in the skeleton due to cross-talk between the bone microenvironment and tumor cells. Bone provides chemotactic factors, adhesion factors, and growth factors that allow the prostate carcinoma cells to target and proliferate in the skeleton. The prostate carcinoma cells reciprocate through production of osteoblastic and osteolytic factors that modulate bone remodeling. The prostate carcinoma-induced osteolysis promotes release of the many growth factors within the bone extracellular matrix thus further enhancing the progression of the metastases. This review focuses on the interaction between the bone and the prostate carcinoma cells that allow for development and progression of prostate carcinoma skeletal metastases.

show abstract

Galactosyl receptor, a cell surface C-type lectin of normal and tumoral prostate epithelial cells with binding affinity to endothelial cells

Cited by 16 publications

References 20 publications

Stromal factors involved in prostate carcinoma metastasis to bone

Stromal factors involved in prostate carcinoma metastasis to bone

Autopsy findings of patients with urological neoplasms

Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone

Contact Info

Product

Resources

About